Shariati A, Khezrpour A, Shariati F, Afkhami H, Yarahmadi A, Alavimanesh S
Front Immunol. 2025; 15:1498431.
PMID: 39872522
PMC: 11769820.
DOI: 10.3389/fimmu.2024.1498431.
Song Y, Wang J, Yang Z, He Q, Bao C, Xie Y
Front Immunol. 2024; 15:1406138.
PMID: 38975334
PMC: 11224535.
DOI: 10.3389/fimmu.2024.1406138.
Kaur A, Vaccari M
Viruses. 2024; 16(3).
PMID: 38543734
PMC: 10974975.
DOI: 10.3390/v16030368.
Al-Qaisi T, Abumsimir B
Future Sci OA. 2023; 9(9):FSO887.
PMID: 37752921
PMC: 10518827.
DOI: 10.2144/fsoa-2023-0090.
Garg I, Sheikh A, Pal S, Shekhar R
Infect Dis Rep. 2022; 14(4):537-546.
PMID: 35893476
PMC: 9326526.
DOI: 10.3390/idr14040057.
Novel personalized cancer vaccine platform based on Bacillus Calmette-Guèrin.
Ylosmaki E, Fusciello M, Martins B, Feola S, Hamdan F, Chiaro J
J Immunother Cancer. 2021; 9(7).
PMID: 34266884
PMC: 8286790.
DOI: 10.1136/jitc-2021-002707.
Vaccine targeting SIVmac251 protease cleavage sites protects macaques against vaginal infection.
Li H, Omange R, Liang B, Toledo N, Hai Y, Liu L
J Clin Invest. 2020; 130(12):6429-6442.
PMID: 32853182
PMC: 7685735.
DOI: 10.1172/JCI138728.
Exploring heterologous prime-boost vaccination approaches to enhance influenza control in pigs.
Li C, Culhane M, Cheeran M, Galina Pantoja L, Jansen M, Amodie D
Vet Res. 2020; 51(1):89.
PMID: 32646490
PMC: 7344353.
DOI: 10.1186/s13567-020-00810-z.
Plague vaccine: recent progress and prospects.
Sun W, Singh A
NPJ Vaccines. 2019; 4:11.
PMID: 30792905
PMC: 6379378.
DOI: 10.1038/s41541-019-0105-9.
Multi-Envelope HIV-1 Vaccine Development: Two Targeted Immune Pathways, One Desired Protective Outcome.
Hurwitz J, Bonsignori M
Viral Immunol. 2018; 31(2):124-132.
PMID: 29315059
PMC: 5915263.
DOI: 10.1089/vim.2017.0144.
The potential of the CMB305 vaccine regimen to target NY-ESO-1 and improve outcomes for synovial sarcoma and myxoid/round cell liposarcoma patients.
Pollack S
Expert Rev Vaccines. 2017; 17(2):107-114.
PMID: 29280411
PMC: 6521962.
DOI: 10.1080/14760584.2018.1419068.
Antibody responses to prime-boost vaccination with an HIV-1 gp145 envelope protein and chimpanzee adenovirus vectors expressing HIV-1 gp140.
Emmer K, Wieczorek L, Tuyishime S, Molnar S, Polonis V, Ertl H
AIDS. 2016; 30(16):2405-2414.
PMID: 27525550
PMC: 5069158.
DOI: 10.1097/QAD.0000000000001224.
Oral Immunization with Recombinant Vaccinia Virus Prime and Intramuscular Protein Boost Provides Protection against Intrarectal Simian-Human Immunodeficiency Virus Challenge in Macaques.
Thippeshappa R, Tian B, Cleveland B, Guo W, Polacino P, Hu S
Clin Vaccine Immunol. 2016; 23(3):204-12.
PMID: 26718849
PMC: 4783425.
DOI: 10.1128/CVI.00597-15.
Murine Monoclonal Antibodies for Antigenic Discrimination of HIV-1 Envelope Proteins.
Sealy R, Jones B, Surman S, Branum K, Howlett N, Flynn P
Viral Immunol. 2015; 29(1):64-70.
PMID: 26544795
PMC: 4717494.
DOI: 10.1089/vim.2015.0078.
Assembly and characterization of gp160-nanodiscs: A new platform for biochemical characterization of HIV envelope spikes.
Nakatani-Webster E, Hu S, Atkins W, Catalano C
J Virol Methods. 2015; 226:15-24.
PMID: 26424619
PMC: 4633331.
DOI: 10.1016/j.jviromet.2015.09.011.
What Has 30 Years of HIV Vaccine Research Taught Us?.
Esparza J
Vaccines (Basel). 2015; 1(4):513-26.
PMID: 26344345
PMC: 4494212.
DOI: 10.3390/vaccines1040513.
A full-length Plasmodium falciparum recombinant circumsporozoite protein expressed by Pseudomonas fluorescens platform as a malaria vaccine candidate.
Noe A, Espinosa D, Li X, Coelho-Dos-Reis J, Funakoshi R, Giardina S
PLoS One. 2014; 9(9):e107764.
PMID: 25247295
PMC: 4172688.
DOI: 10.1371/journal.pone.0107764.
Why primate models matter.
Phillips K, Bales K, Capitanio J, Conley A, Czoty P, t Hart B
Am J Primatol. 2014; 76(9):801-27.
PMID: 24723482
PMC: 4145602.
DOI: 10.1002/ajp.22281.
DNA vaccine prime followed by boost with live attenuated virus significantly improves antigen-specific T cell responses against human cytomegalovirus.
Gil A, Shen S, Coley S, Gibson L, Diamond D, Wang S
Hum Vaccin Immunother. 2013; 9(10):2120-32.
PMID: 24051429
PMC: 3906396.
DOI: 10.4161/hv.25750.
Robust suppression of env-SHIV viremia in Macaca nemestrina by 3-drug ART is independent of timing of initiation during chronic infection.
Peterson C, Younan P, Polacino P, Maurice N, Miller H, Prlic M
J Med Primatol. 2013; 42(5):237-46.
PMID: 24025078
PMC: 3772551.
DOI: 10.1111/jmp.12060.